Amgen Statement on Aranesp Manuscript in the Journal of Clinical OncologyTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan 29, 2008 - Amgen (NASDAQ:AMGN) issued the following statement on the publication of an Aranesp(R) (darbepoetin alfa) manuscript in the January 28, 2008, online issue of the Journal of Clinical Oncology. Amgen anticipates this manuscript will be available in the March 1, 2008, print edition.
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to test whether anemic patients with active cancer not receiving concurrent chemotherapy or radiotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, communicated to physicians through a 'Dear Healthcare Provider' letter, and presented at a scientific conference and other venues throughout last year.
"Amgen is committed to ensuring physicians and their patients have the most up-to-date information on its medicines, including both positive and negative results from clinical trials."
Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)
Posted: January 2008